Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance >= 30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations

MD Levin, A Kater, M Mattsson, S Kersting, J Ranti, HTT Tran, Kazem Nasserinejad, CU Niemann

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article numbere039168
JournalBMJ Open
Issue number10
Publication statusPublished - 2020

Cite this